Maybe you've tried cold turkey twice. Maybe you've tried patches. Maybe someone told you vaping was the answer, or maybe you're skeptical that swapping one nicotine delivery device for another is anything other than changing the shape of the problem.
Both reactions are reasonable. And the evidence is genuinely mixed enough that a simple yes or no would be misleading.
Here's what the research actually shows -- what vaping does and doesn't do for cessation, why the UK and US take different positions, and what to know before making this part of your quit strategy.
What the Research Actually Shows
The most rigorous evidence on vaping for smoking cessation comes from randomized controlled trials and systematic reviews, not observational data.
The Cochrane Evidence
The 2022 update of the Cochrane review on e-cigarettes for smoking cessation (Hartmann-Boyce J et al., 2022) examined 78 studies including 22,052 participants. The headline finding: people assigned to nicotine e-cigarettes were more likely to have quit smoking at 6 months or more than those assigned to NRT.
This is high-certainty evidence by Cochrane standards -- meaning the systematic review authors were confident in the finding. Specifically:
- Nicotine e-cigarettes produced approximately 10 quitters per 100 users at 6 months
- Nicotine patches and other NRT produced approximately 6--7 quitters per 100 users
That's a meaningful difference. It also means that roughly 90% of e-cigarette users in these trials had not quit at 6 months -- which is context that often gets lost in coverage of this research.
The UK NHS Position vs. US FDA Caution
The UK's NHS and National Institute for Health and Care Excellence (NICE) recommend e-cigarettes as a cessation tool, particularly when used alongside behavioral support. The UK's position is grounded primarily in the cessation trial evidence and a harm reduction framework.
The US FDA and CDC take a more cautious position, citing concerns about dual use (especially among adolescents), limited long-term safety data on vaping itself, and the marketing practices of the vaping industry. The US regulatory environment is more restrictive around what cessation claims can be made for e-cigarette products.
Neither position is wrong given their premises. The UK is optimizing for cessation outcomes in current adult smokers. The US is balancing cessation benefit against adolescent uptake and long-term safety unknowns. Understanding this distinction helps make sense of why you might read conflicting headlines.
Harm Reduction vs. Cessation -- An Important Distinction
There are two different goals that switching to vaping might serve, and they're worth distinguishing:
Harm reduction: Replacing combustible cigarettes with vaping to reduce exposure to the most harmful elements of smoking -- tar, carbon monoxide, the combustion byproducts that cause COPD and lung cancer. Nicotine dependence continues, but the damage from combustion is substantially reduced.
Cessation: Using vaping as a stepping stone to becoming nicotine-free entirely.
The evidence is stronger for harm reduction than for cessation-to-nothing. Most people who switch to vaping continue vaping -- often for years. The step from vaping to nicotine-free requires a second cessation process.
This isn't a reason not to switch -- reducing combustion-related harm is a real benefit. But it's important to be clear about which goal you're pursuing. Treating vaping as a permanent alternative to smoking is a different plan from treating it as a bridge to cessation.
What Switching to Vaping Does (and Doesn't) Do
What Improves
When a smoker completely switches to vaping (no combustible cigarettes):
- Carcinogen exposure drops substantially. While vaping aerosol contains some harmful compounds, it does not contain the combustion products -- tar, carbon monoxide, polycyclic aromatic hydrocarbons -- that are responsible for most of smoking's cancer and COPD risk (McNeill A et al., 2022).
- Lung function improves. Studies show measurable improvements in lung function and respiratory symptoms in complete switchers within months.
- Cardiovascular markers improve. Blood pressure, heart rate, and some inflammatory markers trend toward improvement with complete cigarette cessation, even if vaping continues.
- Smell and taste recover. Many former smokers notice significant sensory improvement after switching completely.
What Stays the Same
- Nicotine dependence continues. You are still dependent on nicotine. The oral and behavioral habit structure is maintained, often strengthened by more frequent vaping.
- Long-term vaping safety is unknown. E-cigarettes have been in widespread use for roughly 15 years. Long-term effects (20--30 years) are not yet established. "Less harmful than cigarettes" is not the same as "safe."
- The psychological habit architecture is intact. Switching from smoking to vaping typically preserves rather than disrupts the habitual cue-response pattern.
The Dual-Use Problem
Dual use -- continuing to smoke while also vaping -- is common but provides minimal health benefit. Studies consistently show that the health improvements of switching are largely contingent on complete cessation from combustible cigarettes (McNeill A et al., 2022). If you smoke 10 cigarettes a day and also vape, you have not substantially reduced your combustion-related harm.
For dual users, the goal needs to be complete cigarette cessation first, not indefinite coexistence of both habits.
Who Switching Tends to Help Most
Based on trial and observational data, switching is most likely to be useful for:
- People who have failed multiple times with other methods. If patches, gum, and cold turkey haven't worked, the trial evidence supports trying nicotine e-cigarettes as a cessation-assisted approach.
- People with strong behavioral habit components. The oral and manual components of vaping replicate parts of the smoking ritual. For some smokers, this makes the behavioral transition easier.
- People who primarily need to reduce combustion harm in the near term and are not ready to pursue full nicotine cessation yet. A harm reduction goal is legitimate even if it isn't cessation.
It tends to be less useful for:
- People who are also willing to use NRT effectively (the evidence advantage of vaping over NRT is present but modest).
- Young people who haven't yet developed strong nicotine dependence and could more easily quit with less pharmacological support.
The Long-Term Question -- From Vaping to Nothing
If you switch completely to vaping and want to eventually become nicotine-free, that's a second cessation process -- and it works by the same principles as the first one.
The withdrawal symptoms from stopping vaping are real and follow the same nicotine withdrawal pattern. NRT can help with the transition from vaping to nothing, addressing the pharmacological layer while behavioral work handles the rest.
The path from smoking to vaping to nothing is longer than smoking to nothing directly -- but for many people, it's more achievable, and the harm reduction benefit during the vaping phase is real.
Milo supports people wherever they are in this process -- whether they're quitting smoking, quitting vaping, or figuring out the next step. The CBT framework and craving management approach are the same regardless of what you're quitting.